Glucose metabolism measured by [18f]fluorodeoxyglucose positron emission tomography is independent of PTEN/AKT status in human colon carcinoma cells

Translational Oncology

Volumn 4, Issue 4, 2011, Pages 231-238

  dé Nguyen, Quang ^a   Perumal, Meg ^a   Waldman, Todd A ^b   Aboagye, Eric O ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b GEORGETOWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; GLUCOSE; GLUCOSE TRANSPORTER 1; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B;

ALLELE; ARTICLE; CANCER CELL; CELL PROLIFERATION; COLON CARCINOMA; DRUG UPTAKE; GENE DELETION; GLUCOSE METABOLISM; HUMAN; HUMAN CELL; PHENOTYPE; POSITRON EMISSION TOMOGRAPHY; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT; WILD TYPE;

EID: 79960330197     PISSN: None     EISSN: 19365233     Source Type: Journal    
DOI: 10.1593/tlo.11118     Document Type: Article

References (45)

1. Engelman JA (2009). Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 9, 550-562.
2. Cully M, You H, Levine AJ, and Mak TW (2006). Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat Rev Cancer 6, 184-192.
3. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, Puc J, Miliaresis C, Rodgers L, McCombie R, et al. (1997). PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275, 1943-1947.
4. Steck PA, Pershouse MA, Jasser SA, Yung WK, Lin H, Ligon AH, Langford LA, Baumgard ML, Hattier T, Davis T, et al. (1997). Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 15, 356-362.
5. Cantley LC and Neel BG (1999). New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci USA 96, 4240-4245.
6. Kandel ES, Skeen J, Majewski N, Di Cristofano A, Pandolfi PP, Feliciano CS, Gartel A, and Hay N (2002). Activation of Akt/protein kinase B overcomes a G(2)/M cell cycle checkpoint induced by DNA damage. Mol Cell Biol 22, 7831-7841.
7. Liu P, Cheng H, Roberts TM, and Zhao JJ (2009). Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 8, 627-644.
8. Garcia-Echeverria C and Sellers WR (2008). Drug discovery approaches targeting the PI3K/Akt pathway in cancer. Oncogene 27, 5511-5526.
9. Nguyen Q-D and Aboagye EO (2010). Imaging the life and death of tumors in living subjects: preclinical PET imaging of proliferation and apoptosis. Integr Biol 2, 483-495.
10. Macheda ML, Rogers S, and Best JD (2005). Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J Cell Physiol 202, 654-662.
11. Bentley J, Itchayanan D, Barnes K, McIntosh E, Tang X, Downes CP, Holman GD, Whetton AD, Owen-Lynch PJ, and Baldwin SA (2003). Interleukin-3-mediated cell survival signals include phosphatidylinositol 3-kinase-dependent translocation of the glucose transporter GLUT1 to the cell surface. J Biol Chem 278, 39337-39348.
12. Buerkle A and Weber WA (2008). Imaging of tumor glucose utilization with positron emission tomography. Cancer Metastasis Rev 27, 545-554.
13. Elstrom RL, Bauer DE, Buzzai M, Karnauskas R, Harris MH, Plas DR, Zhuang H, Cinalli RM, Alavi A, Rudin CM, et al. (2004). Akt stimulates aerobic glycolysis in cancer cells. Cancer Res 64, 3892-3899.
14. Gottlob K, Majewski N, Kennedy S, Kandel E, Robey RB, and Hay N (2001). Inhibition of early apoptotic events by Akt/PKB is dependent on the first committed step of glycolysis and mitochondrial hexokinase. Genes Dev 15, 1406-1418.
15. Majumder PK, Febbo PG, Bikoff R, Berger R, Xue Q, McMahon LM, Manola J, Brugarolas J, McDonnell TJ, Golub TR, et al. (2004). M TOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med 10, 594-601.
16. Plas DR, Talapatra S, Edinger AL, Rathmell JC, and Thompson CB (2001). Akt and Bcl-xL promote growth factor-independent survival through distinct effects on mitochondrial physiology. J Biol Chem 276, 12041-12048.
17. Plas DR and Thompson CB (2005). Akt-dependent transformation: there is more to growth than just surviving. Oncogene 24, 7435-7442.
18. Lee C, Kim JS, and Waldman T (2004). PTEN gene targeting reveals a radiationinduced size checkpoint in human cancer cells. Cancer Res 64, 6906-6914.
19. Samuels Y, Diaz LA Jr, Schmidt-Kittler O, Cummins JM, Delong L, Cheong I, Rago C, Huso DL, Lengauer C, Kinzler KW, et al. (2005). Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell 7, 561-573.
20. Workman P, Aboagye EO, Balkwill F, Balmain A, Bruder G, Chaplin DJ, Double JA, Everitt J, Farningham DA, Glennie MJ, et al. (2010). Guidelines for the welfare and use of animals in cancer research. Br J Cancer 102, 1555-1577.
21. Blanco-Aparicio C, Renner O, Leal JF, and Carnero A (2007). PTEN, more than the AKT pathway. Carcinogenesis 28, 1379-1386.
22. Downward J (2004). PI 3-kinase, Akt and cell survival. Semin Cell Dev Biol 15, 177-182.
23. Stiles B, Gilman V, Khanzenzon N, Lesche R, Li A, Qiao R, Liu X, and Wu H (2002). Essential role of AKT-1/protein kinase Bα in PTEN-controlled tumorigenesis. Mol Cell Biol 22, 3842-3851.
24. Blanco-Aparicio C, Perez-Gallego L, Pequeno B, Leal JF, Renner O, and Carnero A (2007). Mice expressing myrAKT1 in the mammary gland develop carcinogen-induced ER-positive mammary tumors that mimic human breast cancer. Carcinogenesis 28, 584-594.
25. Hutchinson J, Jin J, Cardiff RD, Woodgett JR, and Muller WJ (2001). Activation of Akt (protein kinase B) in mammary epithelium provides a critical cell survival signal required for tumor progression. Mol Cell Biol 21, 2203-2212.
26. Lauring J, Cosgrove DP, Fontana S, Gustin JP, Konishi H, Abukhdeir AM, Garay JP, Mohseni M, Wang GM, Higgins MJ, et al. (2010). Knock in of the AKT1 E17K mutation in human breast epithelial cells does not recapitulate oncogenic PIK3CA mutations. Oncogene 29, 2337-2345.
27. Chen Z, Trotman LC, Shaffer D, Lin HK, Dotan ZA, Niki M, Koutcher JA, Scher HI, Ludwig T, Gerald W, et al. (2005). Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 436, 725-730.
28. Kim JS, Lee C, Bonifant CL, Ressom H, and Waldman T (2007). Activation of p53-dependent growth suppression in human cells by mutations in PTEN or PIK3CA. Mol Cell Biol 27, 662-677.
29. Majumder PK, Grisanzio C, O'Connell F, Barry M, Brito JM, Xu Q, Guney I, Berger R, Herman P, Bikoff R, et al. (2008). A prostatic intraepithelial neoplasia- dependent p27Kip1 checkpoint induces senescence and inhibits cell proliferation and cancer progression. Cancer Cell 14, 146-155.
30. Tennant DA, Duran RV, and Gottlieb E (2010). Targeting metabolic transformation for cancer therapy. Nat Rev Cancer 10, 267-277.
31. Vander Heiden MG, Cantley LC, and Thompson CB (2009). Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324, 1029-1033.
32. Yap TA, Garrett MD, Walton MI, Raynaud F, de Bono JS, and Workman P (2008). Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises. Curr Opin Pharmacol 8, 393-412.
33. Vlahos CJ, Matter WF, Hui KY, and Brown RF (1994). A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran- 4-one (LY294002). J Biol Chem 269, 5241-5248.
34. Bleeker FE, Felicioni L, Buttitta F, Lamba S, Cardone L, Rodolfo M, Scarpa A, Leenstra S, Frattini M, Barbareschi M, et al. (2008). AKT1(E17K) in human solid tumours. Oncogene 27, 5648-5650.
35. Abubaker J, Bavi PP, Al-Harbi S, Siraj AK, Al-Dayel F, Uddin S, and Al-Kuraya K (2007). PIK3CA mutations are mutually exclusive with PTEN loss in diffuse large B-cell lymphoma. Leukemia 21, 2368-2370.
36. Saal LH, Holm K, Maurer M, Memeo L, Su T, Wang X, Yu JS, Malmstrom PO, Mansukhani M, Enoksson J, et al. (2005). PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res 65, 2554-2559.
37. Perez-Tenorio G, Alkhori L, Olsson B, Waltersson MA, Nordenskjold B, Rutqvist LE, Skoog L, and Stal O (2007). PIK3CA mutations and PTEN loss correlate with similar prognostic factors and are not mutually exclusive in breast cancer. Clin Cancer Res 13, 3577-3584.
38. Stemke-Hale K, Gonzalez-Angulo AM, Lluch A, Neve RM, Kuo WL, Davies M, Carey M, Hu Z, Guan Y, Sahin A, et al. (2008). An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res 68, 6084-6091.
39. Blanco-Aparicio C, Canamero M, Cecilia Y, Pequeno B, Renner O, Ferrer I, and Carnero A (2010). Exploring the gain of function contribution of AKT to mammary tumorigenesis in mouse models. PLoS One 5, e9305.
40. F]FDG PET. Eur J Nucl Med Mol Imaging 37, 1688-1695.
41. Higashi K, Clavo AC, and Wahl RL (1993). Does FDG uptake measure proliferative activity of human cancer cells? In vitro comparison with DNA flow cytometry and tritiated thymidine uptake. J Nucl Med 34, 414-419.
42. F]]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer 35, 1773-1782.
43. Davies SP, Reddy H, Caivano M, and Cohen P (2000). Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 351, 95-105.
44. Gharbi SI, Zvelebil MJ, Shuttleworth SJ, Hancox T, Saghir N, Timms JF, and Waterfield MD (2007). Exploring the specificity of the PI3K family inhibitor LY294002. Biochem J 404, 15-21.
45. Guillard S, Clarke PA, Te Poele R, Mohri Z, Bjerke L, Valenti M, Raynaud F, Eccles SA, and Workman P (2009). Molecular pharmacology of phosphatidylinositol 3-kinase inhibition in human glioma. Cell Cycle 8, 443-453.